New Haven’s biotech startup focused on brain disease research, Bexorg, has successfully raised $23 million in a Series A funding round. The round was spearheaded by Engine Ventures, with contributions from new investors Connecticut Innovations and E1 Ventures, alongside existing supporters Amplify Partners and Starbloom Capital. Since its inception in 2021, following research at Yale University, Bexorg has accumulated a total of $42.5 million in funding. The company has pioneered a technology platform that utilizes donated human brains to restore specific molecular functions, enabling the testing of potential drug candidates for degenerative diseases like Alzheimer’s and Parkinson’s. CEO and co-founder Zvonimir Vrselja highlighted the significance of investor support, emphasizing Bexorg’s creation of a novel AI-driven, human-brain infrastructure for drug discovery. The funds will be directed towards enhancing the company’s AI engine, which leverages data from brain experiments, and furthering drug discovery and development initiatives. Ann DeWitt from Engine Ventures and David Beyer from Amplify Partners are set to join Bexorg’s board of directors.
Has a New Haven biotech startup raised $23 million?
